About
Antibody-Drug Conjugates, Monoclonals
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Team (6)
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
10
As Collaborator
1
Total Enrollment
1,113
By Phase
PHASE1: 8PHASE1/PHASE2: 1PHASE2: 1PHASE3: 1
By Status
COMPLETED: 7RECRUITING: 3WITHDRAWN: 1
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06932952Lead Sponsor
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
PHASE1Recruiting
85 participants
Started: May 7, 2025 · Completed: Sep 30, 2027
NCT06359002Lead Sponsor
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
PHASE1Recruiting
100 participants
Started: Jun 25, 2024 · Completed: Mar 31, 2027
NCT05737628Lead Sponsor
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
PHASE1Recruiting
100 participants
Started: Mar 4, 2024 · Completed: Dec 1, 2025
NCT05323045Lead Sponsor
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
PHASE1Completed
31 participants
Started: Mar 21, 2022 · Completed: Sep 25, 2024
NCT04983238Lead Sponsor
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
PHASE1/PHASE2Completed
48 participants
Started: Jan 10, 2022 · Completed: Jun 26, 2023
Locations (1)
Headquarters
Nijmegen, Netherlands
Map
Loading map...